As of Feb 05
| -0.18 / -2.87%|
The 3 analysts offering 12-month price forecasts for Oramed Pharmaceuticals Inc have a median target of 18.00, with a high estimate of 25.00 and a low estimate of 15.00. The median estimate represents a +195.57% increase from the last price of 6.09.
The current consensus among 3 polled investment analysts is to Buy stock in Oramed Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.